Table 3 Demographics and clinical characteristics of the test cohort
| Â | All | Survivors | Non-survivors |
|---|---|---|---|
Number of subjects | 135 | 117 | 18 |
Median age in years (25%, 75%) | 2.8 (1.0, 6.7) | 2.7 (1.0, 6.7) | 3.8 (0.9, 7.7) |
Median PRISM score (25%, 75%) | 13 (7, 19) | 12 (7, 18) | 23 (14, 32)1 |
Number of males (%) | 70 (52) | 63 (54) | 7 (39) |
Number of females (%) | 65 (48) | 54 (46) | 11 (61) |
Number for race (%) | Â | Â | Â |
   Caucasian | 113 (84)2 | 99 (85) | 14 (78) |
   African American | 15 (11) | 13 (11) | 2 (11) |
   Other3 | 6 (4) | 4 (3) | 2 (11) |
   Unreported | 1 (1)2 | 1 (1) | 0 (0) |
Number with gram (+) bacteria (%) | 27 (20)2 | 24 (21) | 3 (17) |
Number with gram (-) bacteria (%) | 27 (20) | 22 (19) | 5 (28) |
Number with viral infection (%) | 10 (7) | 9 (8) | 1 (6) |
Number with fungal infection (%) | 2 (1) | 2 (2) | 0 (0) |
Number with no organism isolated (%) | 72 (53)2 | 63 (54) | 9 (50) |
Number with any co-morbidity (%) | 52 (39) | 45 (38) | 7 (39)4 |
Number with meningitis (%) | 5 (4) | 3 (3) | 2 (11) |
Number with cancer (%) | 17 (13) | 14 (12) | 3 (17) |
Number with immune suppression (%) 5 | 13 (10) | 13 (11) | 0 (0) |